Esperion Therapeutics Inc (ESPR): Get It While It’s Cheap
At the end of last week, Amgen, Inc. (NASDAQ:AMGN) announced some data from its large-scale trial of its cardiovascular risk asset Repatha.
Posts Tagged ‘Is AMGN A Good Stock To Buy Right Now?’
Regeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales
Correction: A previous version of this article erroneously presented older events about the case between Sanofi/Regeneron and Amgen.
FDA Approves Amgen, Inc. (AMGN) Drug For Treating Secondary Hyperparathyroidism
Etelcalcetide, an Amgen, Inc. (NASDAQ:AMGN) drug that is meant to treat secondary hyperparathyroidism has been approved by the U.S. Food and Drug Administration.
What’s Next For Esperion Therapeutics Inc (ESPR)?
Esperion Therapeutics Inc (NASDAQ:ESPR) picked up strength at the end of last week, on the back of some news that – at first glance – seems unrelated to its own operations...
Gilead Sciences, Inc. (GILD) Is A Hail Mary: 3 Better Stocks To Consider
After a strong 2015, health care stocks are leading the way lower in 2016. And it’s been an even uglier year for biotechnology company Gilead Sciences, Inc.
Romosozumab From Amgen Inc (AMGN) Shows Positive Results In Osteoporosis
Romosozumab (AKA romo) from Amgen Inc (NASDAQ:AMGN) and Belgium-based UCB, which is in its Phase III FRAME study is yet to achieve any regulatory approval from the FDA until ...
Coherus Biosciences Inc (CHRS) Has Set Its Sights On Amgen, Inc. (AMGN)
Coherus Biosciences Inc (NASDAQ:CHRS) submitted a biologics licensing application (BLA) for its lead biosimilar development candidate earlier this month, and is drawing a lot ...
Coherus Biosciences Inc (CHRS) Is Looking To Compete With Amgen, Inc. (AMGN)’s Cancer Blockbuster
The biosimilar space is relatively young.
